Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02623426 · ClinicalTrials.gov registry record · Phase 3
Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
A Phase 3 study of Uveitis and Macular Edema, sponsored by JHSPH Center for Clinical Trials.
- Completed
- Registry status
- Phase 3
- Development phase
- 194
- Enrollment target
- 20
- Study locations
NCT02623426 is a Phase 3 study of Uveitis and Macular Edema that has completed, run by JHSPH Center for Clinical Trials. The registered enrollment target is 194 participants, below the 607-participant average among 19 other Uveitis trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT02623426, a Phase 3 study of Uveitis and Macular Edema, has completed, sponsored by JHSPH Center for Clinical Trials.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 194 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal methotrexate, intravitreal ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a parallel design (1:1:1), randomized comparative trial with an anniversary close-out after 6 months of follow-up. The primary outcome is percent change in central subfield thickness from the baseline OCT measurement to the 12 week visit.
Conditions Studied
Interventions
- DRUG Dexamethasone intravitreal implant 0.7 mg
- DRUG Intravitreal Methotrexate 400 µg
- DRUG Intravitreal Ranibizumab 0.5 mg
Study Locations (20)
Pennsylvania
- Scheie Eye Institute, University of Pennsylvania - Philadelphia
- MidAtlanitc Retina, Wills Eye Hospital - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
California
- Jules Stein Eye Institute, UCLA - Los Angeles
- University of California, San Francisco - San Francisco
Illinois
- Northwestern University - Chicago
- Rush University Medical Center - Chicago
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
- Ophthalmic Consultants of Boston - Boston
Florida
- Anne Bates Leach Eye Hospital, University of Miami Miller School of Medicine - Miami
Georgia
- Emory University - Atlanta
Iowa
- University of Iowa - Iowa City
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2017-03-09 |
| Est. Completion | 2022-02-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02623426
The ClinicalTrials.gov registry entry for NCT02623426 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 607-participant average among 19 other Uveitis trials with a reported enrollment target (68% lower). The listed sponsor is JHSPH Center for Clinical Trials, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Uveitis appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone intravitreal implant 0.7 mg is the first listed.
NCT02623426 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Pennsylvania, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT02623426 about?
NCT02623426 is a clinical study titled "Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial". The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal methotrexate, intravitreal ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular edema persisting or reoccurring ...
What is the current status of trial NCT02623426?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 194 participants. The study started on 2017-03-09. Estimated completion is 2022-02-02.
What conditions does trial NCT02623426 study?
This clinical trial studies the following conditions: Uveitis, Macular Edema.
What interventions are being tested in trial NCT02623426?
The interventions under investigation include: Dexamethasone intravitreal implant 0.7 mg (DRUG), Intravitreal Methotrexate 400 µg (DRUG), Intravitreal Ranibizumab 0.5 mg (DRUG).
Who is sponsoring clinical trial NCT02623426?
This trial is sponsored by JHSPH Center for Clinical Trials, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02623426 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
RECRUITING · Phase 3
-
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
ACTIVE NOT RECRUITING · Phase 3
-
Study of Difluprednate in the Treatment of Uveitis
COMPLETED · Phase 3
-
Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
COMPLETED · Phase 3
-
PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial
COMPLETED · Phase 3
-
RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.